Key Partnerships

Calidi Biotherapeutics recognizes the importance of forming strong partnerships to drive innovation, conduct clinical trials, and efficiently distribute its products. Key partnerships include:

• Collaboration with research institutions for innovation: Calidi Biotherapeutics actively collaborates with renowned research institutions to leverage cutting-edge technologies and expertise in the field of cell therapy. These partnerships enable the company to stay at the forefront of scientific advancements and develop novel treatment approaches for cancer.
• Partnerships with healthcare providers for clinical trials: In order to validate the safety and efficacy of its therapies, Calidi Biotherapeutics forms partnerships with leading healthcare providers and research facilities to conduct clinical trials. These collaborations are crucial for gathering valuable data, obtaining regulatory approvals, and ultimately bringing new treatments to market.
• Strategic alliances with pharmaceutical companies for distribution: To ensure widespread access to its therapies, Calidi Biotherapeutics forms strategic alliances with pharmaceutical companies for efficient distribution. These partnerships help the company expand its reach, enhance market penetration, and deliver its products to patients in need.

Key Activities

Calidi Biotherapeutics is focused on several key activities that drive innovation and advancement in the field of immunotherapy for cancer treatment.

• Our primary focus is on researching and developing novel immunotherapies that target and eliminate cancer cells while minimizing harm to healthy tissue.
• We invest heavily in cutting-edge technologies and scientific advancements to drive our research efforts and stay at the forefront of the field.
• Our team of dedicated scientists and researchers are constantly exploring new treatment modalities and approaches to enhance the efficacy of cancer immunotherapy.

• We conduct rigorous clinical trials to evaluate the safety and effectiveness of our new cancer treatments in human patients.
• These trials are crucial in determining the viability of our therapies and obtaining regulatory approval for commercialization.
• We collaborate with leading medical centers and research institutions to design and execute clinical trials that adhere to the highest scientific and ethical standards.

• We actively seek strategic partnerships with biopharmaceutical companies, academic institutions, and other organizations to accelerate the development and commercialization of our therapies.
• Collaboration is key to our success, as it allows us to leverage the expertise and resources of our partners to drive innovation and bring new treatments to market faster.
• We maintain strong relationships with key stakeholders in the healthcare and biotechnology industries to foster collaboration and drive progress in cancer immunotherapy.

Key Resources

Calidi Biotherapeutics is equipped with a range of key resources that are essential for the successful development and implementation of our business model. These resources include:

• Expert team of scientists and researchers: At the core of our business model is our team of highly skilled scientists and researchers. With a deep understanding of immunotherapy and a commitment to innovation, our team is able to drive our research and development efforts forward.
• Proprietary immunotherapy technology: Central to our business model is our proprietary immunotherapy technology, which sets us apart from competitors in the field. This technology forms the foundation of our innovative treatments and allows us to address unmet medical needs in the oncology space.
• Funding and investment for research: In order to sustain our research and development activities, we have secured significant funding and investment from strategic partners and investors. This financial support enables us to fuel our growth and advance our pipeline of novel therapies.

Value Propositions

Calidi Biotherapeutics offers innovative immunotherapies for cancer patients, providing a new approach to treating cancer that aims to improve effectiveness and reduce side effects compared to traditional treatments. Our personalized treatment options are tailored to meet the unique needs of each patient, offering a more targeted and precise approach to battling cancer.

Innovative Immunotherapies: Calidi Biotherapeutics is at the forefront of developing cutting-edge immunotherapies that harness the power of the immune system to target and destroy cancer cells. Our therapies offer a novel approach to treating cancer that goes beyond traditional methods, providing patients with new hope for effective treatment.

Improved Effectiveness and Reduced Side Effects: Unlike conventional cancer treatments that can cause harmful side effects and damage healthy cells, Calidi's immunotherapies are designed to specifically target cancer cells while sparing healthy tissue. This targeted approach not only improves the effectiveness of treatment but also minimizes the risk of adverse reactions, leading to a better overall patient experience.

Personalized Treatment Options: Every patient is unique, and their cancer treatment should reflect that. Calidi Biotherapeutics offers personalized treatment options that are tailored to each patient's specific needs and characteristics. By taking into account individual factors such as genetic mutations, tumor characteristics, and immune profiles, we can provide patients with a customized treatment plan that maximizes the likelihood of successful outcomes.

• Increased efficacy
• Reduced side effects
• Personalized treatment options
• Targeted approach to cancer treatment

Customer Relationships

At Calidi Biotherapeutics, we understand the importance of establishing strong and meaningful relationships with our customers, who are primarily patients battling cancer. Our approach to customer relationships is centered around providing support, information, and collaboration with healthcare providers to ensure the best possible outcomes for our patients.

Engagement through patient advocacy groups: We actively engage with patient advocacy groups to connect with and support patients who are in need of our innovative cancer treatments. By partnering with these organizations, we are able to reach a wider audience and provide valuable resources to patients and their families.

Support and information for patients and caregivers: We prioritize providing ongoing support and information to our customers, including patients and caregivers, throughout their treatment journey. This includes educational materials, access to clinical trials, and guidance on managing side effects or other challenges that may arise.

Collaboration with healthcare providers for patient referrals: We work closely with healthcare providers, including oncologists and other specialists, to ensure that patients are referred to us in a timely manner. This collaborative approach helps to streamline the patient referral process and ensures that patients receive the best possible care from our team of experts.

Channels

Calidi Biotherapeutics utilizes a multi-faceted approach to reach its target audience and engage with healthcare professionals. The channels through which the company interacts with key stakeholders include:

• Direct engagement with healthcare professionals: Calidi Biotherapeutics directly communicates with healthcare professionals such as oncologists, hematologists, and other specialists who may be interested in the company's cell-based therapies. This includes one-on-one meetings, presentations, and discussions to educate them about the potential benefits of the company's innovative treatments.
• Participation in medical conferences and seminars: Calidi Biotherapeutics actively participates in national and international medical conferences and seminars related to oncology and cell therapy. The company showcases its research, clinical trials, and successes in these events, allowing it to network with healthcare professionals, researchers, and potential collaborators.
• Digital presence through company website and medical platforms: Calidi Biotherapeutics maintains a strong digital presence through its company website, which serves as a hub for information about its products, pipeline, and upcoming events. The website also features educational content, press releases, and contact information for healthcare professionals interested in learning more about the company's therapies. In addition, the company leverages medical platforms and online communities to engage with healthcare professionals, share insights, and provide updates on its advancements in cell therapy.

Customer Segments

Calidi Biotherapeutics serves several key customer segments within the healthcare industry. These include:

• Cancer patients seeking advanced treatment options: Our primary focus is on providing innovative immunotherapy solutions for cancer patients who are looking for alternative or complementary treatments to traditional options such as chemotherapy or radiation therapy. These patients often have advanced or recurrent forms of cancer and are seeking cutting-edge therapies that can potentially offer better outcomes and fewer side effects.
• Healthcare professionals specializing in oncology: Calidi Biotherapeutics also targets healthcare professionals who specialize in oncology, including oncologists, hematologists, and other specialists who are involved in the care of cancer patients. These professionals are interested in staying abreast of the latest advancements in cancer treatment and may refer their patients to Calidi for immunotherapy options.
• Research institutions interested in immunotherapy studies: In addition, Calidi Biotherapeutics collaborates with research institutions that are conducting studies on immunotherapy and its potential applications in cancer treatment. By partnering with leading academic and scientific organizations, we are able to further advance the field of immunotherapy and contribute to the body of knowledge surrounding this innovative approach to cancer care.

Cost Structure

Calidi Biotherapeutics incurs a number of costs in order to develop its cutting-edge therapies and bring them to market. The primary cost drivers for the company include:

• High research and development expenses: Calidi Biotherapeutics invests heavily in research and development in order to create innovative cancer immunotherapies. This includes costs related to personnel, equipment, facilities, and supplies.
• Costs associated with conducting clinical trials: Before a new therapy can be approved for use, it must undergo rigorous clinical trials to demonstrate its safety and efficacy. This process can be lengthy and expensive, requiring investment in patient recruitment, monitoring, data collection, and regulatory compliance.
• Investment in technology and intellectual property protection: Calidi Biotherapeutics prioritizes protecting its innovations through patents and other intellectual property rights. This incurs costs related to legal fees, filing fees, and ongoing maintenance of intellectual property assets.

These costs are essential in order for Calidi Biotherapeutics to develop and commercialize its therapies, but they also represent a significant financial burden. The company carefully manages its cost structure in order to balance the need for innovation with financial sustainability.

Revenue Streams

Licensing agreements with pharmaceutical companies: Calidi Biotherapeutics generates revenue through licensing agreements with pharmaceutical companies to use their proprietary immunotherapy treatments. These agreements typically involve upfront payments, royalties on sales, and milestone payments based on the success of the treatments.

Sales of immunotherapy treatments: Another significant revenue stream for Calidi Biotherapeutics is the direct sales of their immunotherapy treatments to patients. These treatments are often prescribed by oncologists for patients with certain types of cancer that have not responded well to traditional treatments.

Grants and funding from research institutions: Calidi Biotherapeutics also secures revenue through grants and funding from research institutions. These funds support the ongoing research and development efforts to improve their immunotherapy treatments and bring them to market.

• Licensing agreements with pharmaceutical companies
• Sales of immunotherapy treatments
• Grants and funding from research institutions